Home > Insider Trading > Filing (0001415889-23-013474)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1750284	Olema Pharmaceuticals Inc.	OLMA	Pharmaceutical Preparations (2834)	300409740

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1831216	C. David Myles	C/O Olema Pharmaceuticals, Inc. 780 Brannan St San Francisco CA 94103	Ch. Discov. & Non-Clin Dev Off	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-09-19	20,000	$12.67	572,011	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	12,831	Indirect	See Footnote
Common Stock	154,846	Indirect	See Footnote

Footnotes

The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated June 20, 2023.
The weighted average sale price for the transaction reported was $12.67, and the range of prices were between $12.31 and $12.85. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
Includes 1,446 shares acquired under the issuer's Employee Stock Purchase Plan on May 15, 2022, and 7,664 shares acquired under the issuer's Employee Stock Purchase Plan on May 15, 2023.
The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee.
The shares are held by Myles Properties Inc., of which the Reporting Person is President.